Eosinophilic panniculitis and hypereosinophilia caused by hypersensitivity to calcium heparin

2010 ◽  
Vol 20 (3) ◽  
pp. 401-402 ◽  
Author(s):  
Masahito Yasuda ◽  
Masatoshi Abe ◽  
Masayoshi Yamanaka ◽  
Hiroo Amano ◽  
Atsushi Tamura ◽  
...  
Keyword(s):  
Calcium Heparin

The Interaction of β2 Glycoprotein-I and Heparin and Its Effect on β2 Glycoprotein-I Antiphospholipid Antibody Cofactor Function in Plasma

1994 ◽  
Vol 72 (04) ◽  
pp. 578-581 ◽  
Author(s):  
T McNally ◽  
S E Cotterell ◽  
I J Mackie ◽  
D A Isenberg ◽  
S J Machin
Keyword(s):  
Solid Phase ◽  
Pharmaceutical Preparations ◽  
Enzyme Linked Immunosorbent Assay ◽  
Antiphospholipid Antibody ◽  
Biological Functions ◽  
Dermatan Sulphate ◽  
Glycoprotein I ◽  
Crossed Immunoelectrophoresis ◽  
Calcium Heparin ◽  
Cofactor Activity

Summaryβ2 glycoprotein-I (β2GPI), a cofactor for antiphospholipid antibody (aPA) binding, binds to many anionic macromolecules including heparin. The nature of this interaction with heparin is not well understood and its effect on the purported biological functions of β2GPI is unknown.We have examined the interactions of dermatan sulphate (DS) and different pharmaceutical preparations of heparin with β2GPI by crossed immunoelectrophoresis (CIE) and investigated the effect of these agents on plasma levels of p2GPI antigen (β2GPI: Ag) by a standardised enzyme linked immunosorbent assay (ELISA). P2GPI aPA cofactor activity (β2GPI:Cof) was also measured using a modified solid phase an-ti-phosphatidylserine (aPS) ELISA. CIE results confirmed a heparin-β2GPI interaction with unfractionated (UF) heparin. β2GPI:Ag levels were unaffected by any of the preparations investigated. There were no significant differences in β2GPI:Cof activities of the samples containing LMW heparins or DS but levels of β2GPI:Cof were increased in samples containing UF sodium and calcium heparin preparations (0.5 IU/ml Monoparin, p <0.05, and 10 IU/ml Liquemin and Calcipa-rine, p <0.05).

Comparative Plasma Heparin Levels after Subcutaneous Sodium and Calcium Heparin

1978 ◽  
Vol 40 (02) ◽  
pp. 397-406 ◽  
Author(s):  
Joyce Low ◽  
J C Biggs
Keyword(s):  
Peak Plasma ◽  
Plasma Concentrations ◽  
Factor Xa ◽  
Normal Subjects ◽  
Sodium Salts ◽  
Sodium Heparin ◽  
Significant Difference ◽  
Heparin Plasma ◽  
Calcium Heparin ◽  
Plasma Heparin

SummaryComparative plasma heparin levels were measured in normal subjects injected subcutaneously with 5,000 units of the sodium and calcium salts of heparin. Plasma heparin levels were measured up to 7 hr post-injection by an anti-factor Xa assay (Denson and Bonnar 1973). Preliminary studies indicated that heparin levels were reproducible in subjects who received two injections of the same heparin. Peak plasma concentrations (Cmax) and the time at which peak concentration was reached (Tmax) varied greatly from subject to subject. In one group of subjects (15) two commonly used heparins, a sodium heparin (Evans) and a calcium heparin (Choay) were compared. Peak heparin concentrations were not significantly different. However the Tmax for the sodium heparin (1.5 hr) was significantly earlier than the Tmax for the calcium heparin (3 hr) and this was not due to a difference in the volume of the two heparin injections. No significant difference could be detected in the plasma clearance rate and the molecular weight distribution of the two heparins.In two other groups of subjects, sodium and calcium preparations from two manufacturers were compared. In general, the sodium salts gave rise to significantly higher plasma concentrations, which could be interpreted as a greater bioavailability of sodium salts. These results indicate that the salt of the heparin can influence the plasma concentration achieved after subcutaneous injection.

Analysis Of Subcutaneous Sodium And Calcium Heparin

1981 ◽  
Author(s):  
J A Caprini ◽  
J P Vagher ◽  
L Zuckerman ◽  
J Mitchell
Keyword(s):  
Anticoagulant Activity ◽  
Rapid Onset ◽  
The Other ◽  
Subcutaneous Injections ◽  
Subcutaneous Dose ◽  
Initial Injection ◽  
Calcium Heparin ◽  
To Receive ◽  
Normal Adults ◽  
Clot Time

Thirteen normal adults were randomized to receive a 15,000 unit subcutaneous injection of sodium (Na-hep) or calcium (Ca-hep) heparin and seven days later the experiment was repeated with the other heparin. The APTT, Thrombin-Calcium clot time (TCCT), Lee-White clot time (LWCT) and Heparin 10-A (10-A) assays were determined prior to the injection and 1,2,6, and 10 hours post-injection. With the Na-hep injection, the APTT, TCCT, and LWCT showed a more rapid onset and persistently greater anticoagulant activity during the 10 hour period with statistically significant prolongations for 1 and 2 hour samples. The 10-A activity was higher in the Ca-hep group with significance at 10 hours. All the test values showed anticoagulant activity 1.5 to 2.0 times the control at 10 hours for both heparin preparations.An additional 13 normal adults were randomized to receive 5000 units of Na-hep or Ca-hep subcutaneously every 12 hours for 4 time intervals and after seven days the other heparin preparation was given. The APTT, TCCT, LWCT, and 10-A assays were determined prior to the initial injection and at 2,6,and 10 hours post injections. All APTT values varied between 1 and 1.4 times control with significant elevation at 6 hours in the Ca-hep group. The 10-A assay showed significant differences throughout the study with greater activity in the Na-hep group.We conclude that subcutaneous injections of 5000 units sodium or calcium heparin are bioequivalent despite minor test differences which are magnified by increasing the subcutaneous dose. Therapeutic levels of heparin are maintained for greater than 10 hours following a single 15,000 unit injection and less than 6 hours for 5000 units of either heparin in normal adults. The lack of correlation of either 10-A with other results and the large standard deviation may indicate lack of sensitivity of this assay, rather than differences between heparin salts.

Subcutaneous Heparin in the Prevention of Venous Thrombosis After Elective Aortic Bifurcation Graft Surgery

1979 ◽  
Author(s):  
J.J.F. Belch ◽  
G.D.O. Lowe ◽  
J.G. Pollock ◽  
C.D. Forbes ◽  
C.R.M. Prentice
Keyword(s):  
Venous Thrombosis ◽  
Deep Venous Thrombosis ◽  
Controlled Trial ◽  
Bleeding Complications ◽  
Aortic Bifurcation ◽  
Double Blind ◽  
Risk Of Bleeding ◽  
Subcutaneous Heparin ◽  
Calcium Heparin ◽  
Intravenous Sodium

In a randomised double-blind controlled trial 24 patients undergoing elective aortic bifurcation graft surgery received subcutaneous calcium heparin (2, 500 u preoperatively then 5,000 u 12 hourly or 7 days) and 25 control patients received saline injections. All patients received the routine dose of intravenous sodium heparin intraoperatively. The trial was terminated because of excess bleeding complications in patients on subcutaneous heparin (8 vs. 1, p<0.05). Deep venous thrombosis was diagnosed by 125I-fibrinogen scanning in 8 control patients and 3 patients on heparin (p>0.05). In this group of patients the risk of bleeding due to subcutaneous heparin appeared to outweigh the benefit of thrombotic prophylaxis.

A Comparative Study Of Heparin And A Heparin Analogue In The Prevention Of Thrombosis In Patients With Gynaecological Cancer Under Radiotherapy

1981 ◽  
Author(s):  
R von Hugo ◽  
R Hafter ◽  
H Graeff
Keyword(s):  
Comparative Study ◽  
Controlled Trial ◽  
Gynaecological Cancer ◽  
Heparin Group ◽  
Prophylactic Efficacy ◽  
Prevention Of Thrombosis ◽  
Calcium Heparin ◽  
Fibrinogen Test ◽  
The Difference

The frequency of thrombosis (D.V.T.) in patients treated for gynaecological cancer by combined external irradation and intravaginal radium application, as detected by the 125 I-fibrinogen-test, is considerable (43 % D.V.T.).84 patients undergoing radiotherapy were studied in a first controlled trial to assess the effect of 2×7500 U daily s.c. calcium heparin and 2×5000 U daily s.c. of a semisynthetic heparin analogue (SSHA) on the incidence of D.V.T. during therapy. 4 patients had to be excluded. The frequence of D.V.T. was 15 % (6/40) in the heparin group and 25 % (10/40) in the SSHA group. The difference was not statistically significant.Long term application of prophylaxis (regular radiotherapy lasts 4 weeks) causes discomfort to the patient because of the numerous subcutaneous injections.lt was the aim of a second trial to investigate the prophylactic efficacy of a single s.c. injection per day.80 patients were randomly allocated into two groups and received either 12500 U calcium heparin (n=40) or 12500 U SSHA (n=40). The incidence of D.V.T. was reduced to 15 % by a single heparin injection per day; in patients given SSHA the incidence was 17,5 %.The results presented indicate that SSHA is as effective as heparin in preventing D.V.T. during radiotherapy and that a single s.c. injection per day is sufficient.

CIRCADIAN CHANGES IN THE ANTICOAGULANT EFFECT OF HEPARIN. PHARMACODYNAMIC AND PHARMACOKINETIC EFFECT

1987 ◽  
Author(s):  
H A Decousus ◽  
M F Scully ◽  
J Reynaud ◽  
E Arnaud-Crozat ◽  
C Boissier ◽  
...  
Keyword(s):  
Analysis Of Variance ◽  
Circadian Variation ◽  
Arterial Disease ◽  
The Other ◽  
Pharmacodynamic Effect ◽  
Constant Dose ◽  
Calcium Heparin ◽  
The Mean ◽  
Antifactor Xa ◽  
Heparin Dosage

Six patients, with thromboembolic arterial disease, were prospectively studied to assess the influence of the time of injection of a constant dose of calcium heparin (Choay ), given subcutaneously, on the level of heparin measured by APTT and anti-Xa assay. For each patient, the initial dose of heparin was adjusted by APTT 6h after a morning injection to 1.5 and 2.5 times control. Dose was then kept constant. Four randomized times of injection were tested (8am, 4pm, 8pm and 12pm), in each patient acting as his own control. Blood was sampled via a cannula, at Oh, 2h, 3h,4h,5h,6h, 8h, lOh and 12h after injection. The mean APTT and anti-Xa values for the evening injections (8pm and 12pm) were higher than for the morning injection (8am), at 2h until lOh after injection. These differences were significant (analysis of variance:p<0.001) and reached almost 30 seconds for mean APTT values measured 4h, 5h and 6h after injection. For the afternoon injection (4 pm) the mean APTT and anti-Xa values were intermediate but significantly different from all the other times of injection (analysis of variance: p<0.01).Blood was sampled also on two consecutive days at 12am and 12pm from eight patients receiving heparin subcutaneously for treatment of DVT (administered at 6am and 6pm respectively). Heparin levels by APTT, TT and three antifactor Xa methods (Heptest, Hepaclot, Chromogenic) were significantly higher at night than morning (analysis of variance p<0.005). Cosinor analysis confirmed these results are consistent with circadian variation as we have previously reported after continuous infusion of UF heparin (Br. Med. J., 1985, 290, 341-344). The observed variation was found to be a resultant of a pharmacodynamic effect (circadian variation in assay response to heparin) and pharmacokinetic effect (circadian variation in 99m Tc-heparin clearance). Such circadian variation should be taken into account when deciding heparin dosage.

Three-Month Therapy with Calcium-Heparin in Comparison with Ticlopidine in Patients with Peripheral Arterial Occlusive Disease at Leriche-Fontaine IIb Class

Angiology ◽  
1993 ◽  
Vol 44 (4) ◽  
pp. 307-313 ◽  
Author(s):  
Giuseppe Maria Andreozzi ◽  
Salvatore Santo Signorelli ◽  
Giuseppe Cacciaguerra ◽  
Luigi Di Pino ◽  
Romeo Martini ◽  
...  
Keyword(s):  
Peripheral Arterial Occlusive Disease ◽  
Arterial Occlusive Disease ◽  
Occlusive Disease ◽  
Calcium Heparin ◽  
Peripheral Arterial
Sign in / Sign up

Export Citation Format

Share Document